NCT01419834View on ClinicalTrials.gov

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

August 15, 2011

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions

Neuroblastoma

Interventions

BIOLOGICAL

Humanized 3F8 Monoclonal Antibody (Hu3F8)

Hu3F8 is infused IV over \~30 minutes

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Y-mAbs Therapeutics

All Listed Sponsors

collaborator

Band of Parents

UNKNOWN

collaborator

Y-mAbs Therapeutics

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER